Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing [0.03%]
欧洲药品平均价格的演变：外部参考定价方法的启示
Sabine Vogler,Peter Schneider,Nina Zimmermann
Sabine Vogler
Background: There are indications of staggered market entry of medicines in the national markets, with medicines being marketed first in countries with high prices. This study aimed to analyse the availability and evoluti...
Correction to: Cost-Effectiveness Analysis of Single-Use EEG Cup Electrodes Compared with Reusable EEG Cup Electrodes [0.03%]
对一次性EEG杯电极与可重复使用EEG杯电极的成本效益分析的更正
Anne Sohrt,Anders Mærkedahl,William V Padula
Anne Sohrt
In Figure, the lower branch after the decision node of the decision tree is labelled.
Published Erratum
PharmacoEconomics - open. 2019 Jun;3(2):275. DOI:10.1007/s41669-019-0119-2 2019
Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study [0.03%]
奥马珠单抗治疗重度持续性哮喘的经济性和临床疗效分析：真实世界研究
Luis Manuel Entrenas Costa,Francisco Casas-Maldonado,José Gregorio Soto Campos et al.
Luis Manuel Entrenas Costa et al.
Background: Omalizumab is a fully humanized monoclonal antibody indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma. ...
Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma [0.03%]
metastatic merkle细胞癌的avelumab的成本效益
Ash Bullement,Paul Nathan,Anna Willis et al.
Ash Bullement et al.
Background: Metastatic Merkel cell carcinoma (mMCC) is a rare and aggressive skin cancer. Until recently, there were no licensed treatment options for patients with mMCC, and prognosis was poor. A cost-effectiveness analy...
Check Your Checklist: The Danger of Over- and Underestimating the Quality of Economic Evaluations [0.03%]
检验清单：高估或低估经济评估质量的危险性
Geert W J Frederix
Geert W J Frederix
Estimated Versus Observed Expenditure Associated with Medicines Recommended by the All Wales Medicines Strategy Group [0.03%]
全威尔士医药战略组推荐药物的费用估算与实际支出对比研究
Stuart Keeping,Paul N Deslandes,Kathryn E Haines et al.
Stuart Keeping et al.
Objectives: The All Wales Medicines Strategy Group (AWMSG) appraises the clinical and cost effectiveness of new medicines being considered for National Health Service (NHS) prescribing in Wales (UK). The aim of this study...
The Worth of a Quality-Adjusted Life-Year in Patients with Diabetes: An Investigation Study using a Willingness-to-Pay Method [0.03%]
糖尿病患者的质量调整生命年的价值：一项使用支付意愿法进行的调查研究
Najme Moradi,Arash Rashidian,Shirin Nosratnejad et al.
Najme Moradi et al.
Background: A limited number of studies have specifically examined the value of quality-adjusted life-years (QALYs) from the patient's perspective. Object...
A Review of Issues Affecting the Efficiency of Decision Making in the NICE Single Technology Appraisal Process [0.03%]
英国NICE单一科技评估过程中影响决策效率的因素分析综述
M J Walton,J O&#x;Connor,C Carroll et al.
M J Walton et al.
Background: Escalating demands upon the National Institute for Health and Care Excellence's (NICE's) Single Technology Appraisal (STA) programme require a 2.5-times increase upon 2015 capacity by 2020. This additional str...
Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada [0.03%]
加拿大纳武单抗联合伊匹木单抗一线治疗晚期黑色素瘤的经济评价研究报告
Peter L Quon,Ying Xiao,Sonja Sorensen et al.
Peter L Quon et al.
Objective: Our objective was to evaluate the cost effectiveness of the combination of nivolumab and ipilimumab, referred to as "Regimen", as a first-line treatment for patients with advanced melanoma from the perspective ...
The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q [0.03%]
英国医保报销中真实世界证据的作用——来那度胺在染色体5号缺失的骨髓增生异常综合征患者中的应用案例研究
Dawn Lee,Nic Brereton,Sujith Dhanasiri et al.
Dawn Lee et al.
Background: Uncertainty within cost-effectiveness analysis, often driven by lack of mature data from large clinical trials, plays a key role in decisions made by the National Institute for Health and Care Excellence (NICE...